Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis [PDF]
, 2021 Teiko Sakurai +8 more
openalex +1 more source
Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis [PDF]
, 2015 C Ellender +4 more
openalex +1 more source
Data Supplement from Src Kinase Is a Novel Therapeutic Target in Lymphangioleiomyomatosis [PDF]
, 2023 Alexey Tyryshkin +2 more
openalex +1 more source
Pulmonary Lymphangioleiomyomatosis [PDF]
Pneumologie, 2002 U, Costabel, J, Guzman
openaire +2 more sources
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. [PDF]
, 2016 BackgroundEverolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, is used to treat solid tumors and tuberous sclerosis complex (TSC). Stomatitis, an inflammation of the mucous membranes of the mouth, is a common adverse event associated with ...
Anak, O +10 more
core
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis [PDF]
, 2017 Angelo M. Taveira‐DaSilva +4 more
openalex +1 more source
Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis
BiomoleculesLymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common.
Stella Bähr +6 more
doaj +1 more source
Only those who attempt the absurd will reach the impossible. High-flow nasal cannula oxygen therapy alone during weaning after extubation in a patient with tuberous sclerosis complex and lymphangioleiomyomatosis [PDF]
, 2020 Maurizia Lanza +4 more
openalex +1 more source
Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis [PDF]
, 2021 Koichi Nishino +14 more
openalex +1 more source